Erik Atkisson - 30 Sep 2021 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.

Role
GC & Chief Compliance Officer
Signature
/s/ Sriram Ryali, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
30 Sep 2021
Net transactions value
$0
Form type
4
Filing time
01 Oct 2021, 16:35:28 UTC
Previous filing
01 Oct 2021
Next filing
11 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EIGR Stock Option (Right to Buy) Award $0 +180,000 $0.000000 180,000 30 Sep 2021 Common Stock 180,000 $6.68 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as follows: 25% of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of September 20, 2021, with the remaining shares to vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date.